fgi-106 fgi-106 fgi-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped rna viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. it acts as an inhibitor which blocks viral entry into host cells. in animal tests fgi-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses hantavirus, rift valley fever virus and crimean-congo hemorrhagic fever virus, the flavivirus dengue virus, and the filoviruses ebola virus and marburg virus. fgi-106legal statuslegal status us: investigational new drug identifiers iupac name n1,n7-bis-3,9-dimethylquinolinoquinoline-1,7-diamine cas number501081-38-5 ypubchem cid432342chemspider382357uniibrt994456wchemical and physical dataformulac28h38n6molar mass458.640 g·mol−13d model (jsmol)interactive image smiles cn(c)cccnc(c2ccc14)cc(c)nc2c1ccc3c4nc(c)cc3ncccn(c)c inchi inchi=1s/c28h38n6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18h,7-8,13-16h2,1-6h3,(h,29,31)(h,30,32)key:wjupenlnvuceth-uhfffaoysa-n